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The discovery of the endocannabinoid system has raised public interest in the medicinal use of cannabis, phytocannabinoids, 
and synthetic cannabinoids, which has always been closely regulated due to their psychotropic effects and potential abuse. 
The review takes a quick look at the current legal framework in the European Union, which regulates cannabis use and 
cultivation for medicinal purposes in line with the United Nations Conventions on the production, trade, and use of 
cannabis, phytocannabinoids, and synthetic cannabinoids. And while the EU legislation precisely defines requirements 
and marketing authorisation procedures for medicinal products for all EU member states, there is no common regulatory 
framework for magistral and officinal preparations containing cannabinoids, as they are exempt from marketing 
authorisation. Instead, their regulation is left to each member state, and it is quite uneven at this point, mainly due to 
cultural and historical differences between the countries, leading to different access to non-authorised medicinal products. 
Therefore, to meet great public interest, harmonised approaches on cannabinoid-containing products without marketing 
authorisation would be welcome to level the playing field in the EU.
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Different species of the genus Cannabis make part of 
human life since ancient times. Industrial cannabis (hemp) 
and medicinal cannabis (marijuana) are genetically distinct 
forms of the plant Cannabis sativa L., the major difference 
between them being the content of psychoactive compounds. 
While hemp contains no more than 0.2 % of psychoactive 
Δ9-tetrahydrocannabinol (THC) weight per weight (w/w), 
medicinal cannabis contains more (1). Hemp is usually 
cultivated for the production of a wide range of industrial 
products like fibres in textiles, paper, and construction 
materials or seeds in foodstuffs, whereas marijuana has a 
long history of cultivation for psychotropic (religious or 
medicinal) use (2, 3).
At the beginning of the twentieth century, the medicinal 
use of cannabis had largely declined (1), but the discovery 
of the endocannabinoid system has recently revived interest 
in the potential therapeutic use of various cannabinoid 
derivatives (4). The problem, however, is the abuse of 
cannabis over its psychotropic effects. As it may pose a 
serious risk to public health, it has long been regulated by 
legislation, and cannabis and phytocannabinoid-containing 
products are the most commonly used illicit drugs in the 
world. However, laws regulating the safe use of 
phytocannabinoids differ greatly between countries, 
reflecting a variety of historical and cultural backgrounds 
(3, 4). The aim of this article is to review current legislation, 
focusing on the use of medicines and cannabis cultivation 
in the European Union (EU) and to show in what areas the 
legislation of medicinal products containing cannabinoids 
varies across EU countries, leading to different accessibility 
to these products.
CANNABIS AND CANNABINOIDS IN 
MEDICINE
Ever since the nineteenth century approval of the use 
of cannabis tincture to relieve pain and nausea in Britain 
(5), most countries allow medicinal use of cannabinoids as 
one of the legal treatment options (1). By definition, 
cannabinoids are substances that bind the cannabinoid 
receptors of the body and trigger similar effects to those 
evoked by the plant C. sativa (3). They are most often 
classified according to their origin and structure.
Endocannabinoids are endogenous neurotransmitters 
that bind to cannabinoid CB1 and CB2 receptors in the 
mammalian central and peripheral nervous system. In the 
past 15 years, they have been shown to share metabolic 
pathways and molecular targets with a number of lipid 
mediators. They make a complex system, described as 
endocannabidiome, which regulates several physiological 
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processes. These include pain, cognition, motor activity, 
appetite, nausea, vomiting, and some endocrine, 
inflammatory, and immune reactions. Endocannabidiome 
receptors and metabolic enzyme targets can therefore be 
useful in the treatment of various symptoms and diseases 
such as pain, nausea, depression, anxiety, and neurological 
disorders like multiple sclerosis and epilepsy (6–8).
Phytocannabinoids are the first known psychoactive 
cannabinoids. They are components of C. sativa and some 
other plant species. So far, there are over 100 known 
phytocannabinoids, some of which are present in plants in 
very  low concentra t ions .  The most  abundant 
phytocannabinoid, readily extracted from C. sativa is the 
psychoactive Δ9-tetrahydrocannabinol (THC). Other 
common phytocannabinoids are not psychoactive and 
include cannabidiol (CBD), cannabigerol (CBG), and 
cannabichromene (CBC) (9).
Syntethic cannabinoids have been used in medicine 
since the second half of the 20th century. Historically, they 
are based on the structure of phytocannabinoids, but this is 
not true of newer synthetic compounds. Currently, there are 
two products containing synthetic cannabinoids that have 
been approved for medicinal use in some EU member states: 
dronabinol, which is synthetic THC, and nabilone, which 
is a synthetic analogue to THC (Table 1). Current drug 
research is mainly based on synthetic cannabinoids. Besides 
medicinal use, several CB1 receptor-selective agonists have 
been developed as psychoactive ingredients in products for 
recreational use. Since little is known about their effects in 
humans, and since some of them cause more distress and 
panic than phytocannabinoids, they represent a significant 
health risk (10–13).
LEGISLATION OF CANNABINOID-BASED 
MEDICINAL PRODUCTS
Legislation on cannabis issues is nearly 100 years old. 
When cannabis came under international control under the 
revised International Opium Convention of 1925, it was 
referred to as ‘Indian hemp’. The Convention referred only 
to the dried tops of the pistillate plant, particularly rich in 
‘pharmaceutically strong active resin’ and banned the export 
of cannabis resin to countries that prohibited its use and 
established domestic control, such as penalties for 
unauthorised possession of cannabis extract and tincture. 
The Convention also proposed that any breaches of national 
laws should be penalised (14). 
Three United Nations (UN) conventions, signed by all 
EU member states, outline the basic framework for 
controlling the production, trade, and possession of over 
240 psychoactive substances, many of which have 
therapeutic potential. These conventions classify narcotic 
drugs and psychotropic substances, including cannabis, 
according to their danger to health, risk of abuse, and 
therapeutic value.
The first, 1961 Single Convention on Narcotic Drugs 
(15), classified narcotic drugs and seeks to combat drug 
abuse through concerted international measures. It proposed 
two forms of intervention and control with the aim to: a) 
limit the possession, use, trade, distribution, import, export, 
and production of drugs exclusively for medical and 
scientific purposes; and b) combat drug trafficking through 
international cooperation. The Convention did not differ 
between industrial hemp and medicinal cannabis and 
classified cannabis in Schedule I as a substance presenting 
a serious risk of abuse, whose properties give rise to 
dependence. Cannabis was also included in Schedule IV 
among the most dangerous substances due to their 
particularly harmful characteristics, the risks of abuse, and 
limited therapeutic value. This significantly limited the use 
of cannabis and cannabinoids for medicinal purposes, which 
has later raised a number of controversies (16).
The 1971 UN Convention on Psychotropic Substances 
(17) included new, synthetic drugs of abuse, such as 
synthetic cannabinoids, taking into account their abuse 
potential as well as their therapeutic value.
The 1988 UN Convention against Illicit Traffic in 
Narcotic Drugs and Psychotropic Substances (18) has 
established comprehensive international measures against 
drug trafficking, money laundering, and abuse of drug 
precursors. The Convention also binds member countries 
to prevent illicit cannabis cultivation and to eradicate 
cannabis plants on their territory.
These three conventions, however, do not specify that 
drug use should be a punishable offence. Instead, each 
country is free to regulate this issue. In addition, the 
conventions do not associate drug types with the severity 
of penalties and even though the schedules affect the 
procedures for the legal trade of the drugs, the countries are 
not bound to use them.
International drug control has evolved, and nowadays 
it does not ban cannabis or cannabis-based product use in 
medicine to treat specific indications. While international 
law provides a general regulatory framework for the 
cultivation and marketing of cannabis, the EU law sets the 
criteria for medicinal products, including those containing 
cannabinoids, to be authorised for marketing in the EU 
member states. However, magistral and officinal formulas 
are exempt from the EU marketing authorisation rules and 
are left to the care of the EU member states. This eventually 
leads to different access for patients to these medicinal 
products containing cannabinoids in the EU countries.
EU AND MEMBER STATE LEGISLATION
Cannabis and cannabinoids have their place in 
pharmacotherapy in the EU member states. They are mostly 
indicated for treating chronic pain, nausea, and vomiting 
due to chemotherapy or to relax muscle stiffening caused 
by multiple sclerosis (7, 19, 20). They occur in various 
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Cannabinoid-containing products with no marketing 
authorisation
According to its article 3, the Directive 2001/83/EC 
(21) does not apply to magistral and officinal formulas and 
leaves their regulation to the jurisdictions of member states, 
which may include a wide range of cannabinoid-containing 
products (1).
In most EU countries this exemption enables pharmacists 
to prepare magistral formulas for use in accordance with a 
specified medical prescription for an individual patient. It 
also allows the production of larger batches (officinal 
formulas, aka stock or standardised preparations) in 
accordance with national pharmacopoeia or national 
formularies. Although it is uncommon in the EU member 
states to use raw cannabis for medicinal purposes, some 
countries allow patients access to officinal cannabis 
preparations such as Croatia, Czech Republic, Denmark, 
Finland, Germany, Italy, Luxembourg, Netherland, Poland, 
and Sweden (1, 27–31). Magistral preparations are also 
available through special access schemes in Czech 
Republic, Germany, Italy, and the Netherlands and through 
exceptional/compassionate use programmes in Croatia, 
Denmark, Finland, Poland, and Sweden. These approaches 
enable medical approval and oversight, limit medicinal use 
to a specific set of medical conditions, and generally restrict 
the use of cannabis preparations. Their use may further be 
restricted by lack of health insurance coverage, as national 
regulatory frameworks are not always clear about how 
officinal and magistral preparations should work in practice. 
For example, officinal (standard) preparations in Estonia 
need approval by the Estonian State Agency of Medicines; 
in Finland, officinal preparations with nabiximols are 
allowed; in Sweden, only a small number of patients are 
granted permission to use cannabis preparations (1). In 
addition, some EU member states like Germany have 
pharmacopoeias and/or formularies (32) which include 
formulations, yet some products have a marketing 
authorisation for medicinal use and others do not (Figure 
1) (1).
Cannabinoid-containing products with marketing 
authorisation
The EU legal framework for authorised medicinal 
products for human use has been laid down by the Directive 
2001/83/EC of the European Parliament and of the Council 
and its amendments (21). All of the cannabinoid-based 
medicines that pass the centralised procedure for marketing 
authorisation can be marketed in all the EU member states 
and prescribed by physicians according to their approved 
indications and posology. So far, only one cannabinoid-
based product with a trade name Epidyolex (containing 
10 % of CBD isolated from cannabis) has been approved 
for the treatment of intractable childhood epilepsy by the 
European Medicines Agency (EMA) in 2019 and received 
the orphan drug designation in 2014 (Table 1) (22, 23).
Beside the centralised EMA procedure for marketing 
authorisation, cannabinoid-based products can be authorised 
through a decentralised procedure, mutual recognition 
procedure, or national procedures of the member states, 
which limit their use to the market of the member state 
involved in the procedure. Having a marketing authorisation 
implies that the product has been tested for safety and 
efficacy through extensive non-clinical and clinical trials. 
Regulatory authorities also consider whether the product 
meets the required level of quality. So far, there are but a 
few authorised medicinal products containing nabiximols, 
dronabinol, or nabilone on the EU member state markets 
(Table 1) (22–26). Other cannabinoid-based medicines are 
in different stages of development but have not yet been 
authorised for marketing.
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monographs for the preparation of cannabis extracts, and 
some like Slovenia do not. This is why magistral and 
officinal formulas cannot be prescribed in Slovenia (33, 34) 
and can in Germany. These discrepancies could be 
overcome by harmonising relevant European pharmacopoeia 
monographs.
LEGAL FRAMEWORK FOR CANNABIS 
CULTIVATION FOR MEDICINAL 
PURPOSES AND FOOD PRODUCTS
International law does not ban the cultivation of 
cannabis for medicinal use. Instead, the 1961 UN 
Convention provides a general system of control, if a 
country decides to grant cannabis cultivation not intended 
for industrial or horticultural purposes. Each country has 
the exclusive right to buy the entire cannabis production on 
its territory (15). Cultivation and primary processing of 
cannabis directly influence the quality of active 
pharmaceutical ingredients and should therefore comply 
with the provisions of the UN Conventions and the WHO 
guidelines of good agricultural and collection practices (35) 
for medicinal plants. For the EU member states EMA 
additionally provides Guidelines on Good Agricultural and 
Collection Practices (GACP) (36) that include a system of 
quality control of medicinal plants and herbal substances 
from cultivation to distribution.
Cultivation of medicinal cannabis in the EU is currently 
allowed in Austria, Czech Republic, Italy, Germany, Greece, 
Malta, the Netherlands, and Portugal. All of these member 
states have established an authority for cannabis cultivation 
and defined their responsibilities as summarised in Table 2 
(1, 27, 37–40).
Hemp can also be cultivated in the EU for food, 
provided that it is registered in the EU’s Common Catalogue 
of Varieties of Agricultural Plant Species (41) and that its 
THC content does not exceed 0.2 % w/w. Furthermore, in 
the Novel Food catalogue (42) the EC has listed C. sativa 
extracts with cannabidiol content higher than in hemp, and 
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them banned in food, including dietary supplements, until 
safety assessment is completed.
CONCLUSIONS
The growing interest in the use of cannabis and 
cannabinoid products forces countries to regulate cultivation 
and safe use of cannabis and its products for medicinal use. 
The basic regulatory framework is provided by the UN 
conventions, whereas the EU legislation covers only 
medicinal products that have been authorised for marketing. 
The regulation of cannabinoid-containing products without 
marketing authorisation – magistral and officinal 
(standardised) preparations – is left to each EU member 
state and is quite uneven across the EU, mainly due to 
cultural and historical differences between the countries. 
There are different approaches to this kind of regulation 
that cannot be easily transferred from one EU country to 
another, yet uneven availability of cannabinoid-containing 
medicinal products calls for some harmonisation of these 
approaches to level the playing field and avoid issues such 
as cross-border patient access where EU countries have 
different regulatory schemes.
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Kanabis in kanabinoidi v medicini – zakonodajni vidik
Odkritje endokanabinoidnega sistema je vzbudilo zanimanje javnosti za medicinsko uporabo konoplje, fitokanabinoidov 
in sintetičnih kanabinoidov, ki je bila zaradi psihotropnih učinkov in morebitne zlorabe že od nekdaj natančno regulirana. 
V prispevku je predstavljen pravni okvir Evropske unije, ki ureja uporabo in gojenje konoplje v medicinske namene, v 
skladu s konvencijami Združenih narodov o proizvodnji, trgovini in uporabi konoplje, fitokanabinoidov in sintetičnih 
kanabinoidov. Medtem ko zakonodaja Evropske unije natančno določa zahteve in postopke izdaje dovoljenja za promet 
za avtorizirana zdravila, ni skupnega regulatornega okvira za magistralne in oficinalne pripravke, ki so izvzeti iz 
avtorizacijskih postopkov. Njihova ureditev je prepuščena vsaki državi članici in se zaradi tega razlikuje, predvsem zaradi 
kulturnih in zgodovinskih razlik med državami, to pa vodi do različne dostopnosti do tovrstnih zdravil. Zaradi tega bi 
bili dobrodošli nekateri usklajeni pristopi držav članic EU, s katerimi bi zmanjšali razlike na trgu neavtoriziranih zdravil 
s kanabinoidi.
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